<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: According to the 7th edition of the TNM staging system, stage IV <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) at the time of initial diagnosis is sub-classified into stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IVA</z:e> or <z:mp ids='MP_0010560'>IVB</z:mp> disease </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">Peritoneal carcinomatosis</z:e> (PC), considered to have a dismal prognosis, is exclusively sub-classified into stage <z:mp ids='MP_0010560'>IVB</z:mp>, even though other <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> to a sole organ are sub-classified into stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IVA</z:e>, which is considered to be associated with better survival </plain></SENT>
<SENT sid="2" pm="."><plain>This retrospective study was undertaken to investigate the overall survival in metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, focusing on PC patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We reviewed data on patients with metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> at initial diagnosis surgically treated between January 2006 and June 2011 </plain></SENT>
<SENT sid="4" pm="."><plain>A survival analysis was performed paying special attention to PC and sub-classifying patients with PC into three categories according to metastatic sites </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: There were 69 stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IVA</z:e> patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IVA</z:e> group) and 83 stage <z:mp ids='MP_0010560'>IVB</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Among stage <z:mp ids='MP_0010560'>IVB</z:mp> patients, 20 had isolated PC (PC-I group), 28 had PC with one or more other sites of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (PC-II group), and 35 had at least 2 metastatic without peritoneal involvement (NPC group) </plain></SENT>
<SENT sid="7" pm="."><plain>Of 152 stage IV patients, 132 (87 %) underwent resection of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and 19 (12 %) underwent radical resection of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> with microscopic free margins (R0 resection) including 5/20 (25 %) patients in the PC1 group </plain></SENT>
<SENT sid="8" pm="."><plain>A total of 139 patients received <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy in a palliative (n = 125), neoadjuvant (n = 3), or adjuvant setting after R0 resection (n = 11) </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with 36.6 months in the PC-I group, median survival was 32.5 months (P = 0.48) in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IVA</z:e> group, 14.7 months (P = 0.07) in the PC-II group, and 12.9 months (P &lt; 0.01) in the NPC group </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The sub-classification of isolated PC into stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IVA</z:e> instead of <z:mp ids='MP_0010560'>IVB</z:mp> might be more appropriate in the era of modern chemotherapy </plain></SENT>
<SENT sid="11" pm="."><plain>Further investigation is warranted </plain></SENT>
</text></document>